Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q4 2014 · 10-K
Revenue$2.64B$2.64B+34.3% vs Q4 2013 Net Income$883.50M$883.50M+93.2% vs Q4 2013 EPS Diluted$3.74$3.74+94.8% vs Q4 2013 Gross Profit$2,343,400,000+37.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$932,848,000+7.3% Free Cash Flowderived$825,902,000+4.5% Margins · derivedGross margin88.7%+1.9 pt vs Q4 2013
Operating margin43.9%+10.5 pt vs Q4 2013
Net margin33.5%+10.2 pt vs Q4 2013
ended Dec 31, 2014 · filed Feb 4, 2015 · 35 d after period end